Zobrazeno 1 - 10
of 58
pro vyhledávání: '"U. Thyroff-Friesinger"'
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 47:391-401
Objective: To compare the steady-state pharmacokinetics and pharmacodynamics following multiple subcutaneous administration of a new erythropoiesis stimulating agent (HX575, Binocrit ® , Sandoz GmbH, Holzkirchen, Germany) with that of epoetin beta (
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 43:457-462
Background: The choice of an appropriate reference product is still a problem within the European Union. When no direct comparisons between originator products in different countries are available, registration authorities are sometimes only prepared
Autor:
Rossen Koytchev, V Vlahov, E. Rehak, U. Thyroff-Friesinger, R.-G. Alken, Valentin Kirkov, R. Kaneva
Publikováno v:
European Journal of Clinical Pharmacology. 54:469-474
The aim of the present paper was to compare the pharmacokinetics of metoprolol in homozygous Caucasian volunteers for the wild-type CYP2D6 allele (CYP2D6*1/CYP2D6*1) and heterozygous (CYP2D6*1/CYP2D6*4) Caucasians.Thirty-six unrelated healthy male Ca
Publikováno v:
Pharmacological Research. 34:149-152
The bioequivalence of three different formulations of mefenamic acid was tested using the index zeta 2 previously defined by Rescigno. This index is a measure of the distance in Hilbert space of two concentration vs time functions; unlike the approac
Publikováno v:
Clinical nephrology. 72(5)
The recombinant human epoetin-a HX575 (Sandoz Pharmaceuticals GmbH/Hexal AG, Holzkirchen, Germany) is the first biosimilar erythropoiesis-stimulating agent (ESA) with marketing authorization in Europe. The primary objective of the study was the evalu
Autor:
N. Dauletbaev, P. Fischer, U. Thyroff-Friesinger, J. Bargon, J. Gross, B. Aulbach, W. Kusche, Tof Wagner
Publikováno v:
European Journal of Medical Research, Vol 14, Iss 8, p 352 (2009)
European Journal of Medical Research
European Journal of Medical Research
Objective We conducted a single-centre, randomised, double-blinded, placebo-controlled phase II clinical study to test safety and efficacy of a 12-week therapy with low-dose (700 mg/daily) or high-dose (2800 mg/daily) of NAC. Methods Twenty-one patie
Autor:
K. G. Naber, U Thyroff-Friesinger
Publikováno v:
Infection. 18:S70-S76
20 urologists took part in a single blind, randomized study. Female patients with acute uncomplicated UTI were recruited. The patients received either a single dose of 3 g fosfomycin trometamol versus 200 mg ofloxacin or 1.92 g co-trimoxazole. Follow
Autor:
F X Kleber, U Thyroff-Friesinger
Publikováno v:
Cardiology. 77:67-74
This multicentre, double-blind, double-dummy, randomised parallel group study in 247 patients with mild chronic congestive heart failure compared the efficacy and tolerability of ibopamine, hydrochlorothiazide (HCTZ), ibopamine plus HCTZ and placebo
Autor:
U. Thyroff-Friesinger, F.X. Kleber
Publikováno v:
Cardiology. 77:75-80
We describe a randomized double-blind 4-week study on the efficacy of monotherapy with ibopamine 200 mg b.i.d. in comparison to placebo and open titrated digoxin in patients with mild congestive heart failure NYHA class I and II. A total of 60 patien
Publikováno v:
Thorax. 70:A9.1-A9
Introduction and objectives Guideline-defined asthma control may be achieved and maintained in the majority of patients by treatment with a combination of a corticosteroid and a long-acting s2-agonist. AirFluSal® Forspiro®, a multi-dose dry powder